10-12 D\u00e9cembre 2024
\nBoston, MA, Etats-Unis<\/p>\n
ENYO Pharma participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares.
\nENYO Pharma pr\u00e9sentera son \u00e9tude clinique de Phase 2 ALPESTRIA-1 qui a d\u00e9marr\u00e9 cet \u00e9t\u00e9 avec Vonafexor pour les patients atteints du syndrome d’Alport.<\/p>\n
https:\/\/rare-kidney-drug-development.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 10-12 D\u00e9cembre 2024 ENYO Pharma participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares. Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5791","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"10-12 D\u00e9cembre 2024 Boston, MA, Etats-Unis ENYO Pharma participera pour la premi\u00e8re fois au 4th Rare & Genetic Kidney Disease Drug Development Summit, Boston (US). Cet \u00e9v\u00e8nement regroupera des industriels, KOL acad\u00e9miques et repr\u00e9sentants de patients atteints de maladies r\u00e9nales pour acc\u00e9l\u00e9rer la recherche clinique concernant les maladies r\u00e9nales rares. ENYO Pharma pr\u00e9sentera son \u00e9tude…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5791"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791\/revisions"}],"predecessor-version":[{"id":5799,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5791\/revisions\/5799"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nBoston, MA, Etats-Unis<\/p>\n
\nENYO Pharma pr\u00e9sentera son \u00e9tude clinique de Phase 2 ALPESTRIA-1 qui a d\u00e9marr\u00e9 cet \u00e9t\u00e9 avec Vonafexor pour les patients atteints du syndrome d’Alport.<\/p>\n